With plans to refocus on its supply chain and clinical products, Cardinal Health (Dublin, OH) has sold
its drug manufacturing unit to Blackstone Group for $3.3 billion. Cardinal still plans on keeping two of its businesses that support generic drugs, however. The announcement sent the company'sÂ shares up nearly 3.4 percent. The sale is part of Cardinal Health's committment
to making healthcare "safer and more productive," according to Cardinal President and CEO R. Kerry Clark. Cardinal Health's medical device business, which generates $1.6 billion in revenue, includes surgical instruments, gloves, interventional radiology products, and respiratory care products.